SymBio Pharmaceuticals (TSE:4582) Inventories, Raw Materials & Components: 円58 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
27 GF Score
Price 円64.00
GF Value 円43.47
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Inventories, Raw Materials & Components?

SymBio Pharmaceuticals TSE:4582 +1.59% 27 Inventories, Raw Materials & Components is 円58 Mil as of Jun. 2026. GuruFocus rates TSE:4582 with a GF Score™ of 27/100 and a GF Value™ of 円43.47 (Significantly Overvalued). The stock has 4 warning signs investors should review.

SymBio Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Jun. 2026 was 円58 Mil.

SymBio Pharmaceuticals's quarterly raw materials declined from Dec. 2025 (円136 Mil) to Mar. 2026 (円60 Mil) and declined from Mar. 2026 (円60 Mil) to Jun. 2026 (円58 Mil).

SymBio Pharmaceuticals's annual raw materials increased from Dec. 2023 (円0 Mil) to Dec. 2024 (円62 Mil) and increased from Dec. 2024 (円62 Mil) to Dec. 2025 (円136 Mil).

SymBio Pharmaceuticals Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Inventories, Raw Materials & Components Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.45 0.38 61.93 136.40

SymBio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.44 136.49 136.40 59.99 58.39
TSE:4582
27GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of 円58 Mil mean?
SymBio Pharmaceuticals (TSE:4582) has a Inventories, Raw Materials & Components of 円58 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Inventories, Raw Materials & Components too high?
SymBio Pharmaceuticals' current Inventories, Raw Materials & Components is 円58 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Inventories, Raw Materials & Components compare to ZTS?
SymBio Pharmaceuticals' Inventories, Raw Materials & Components of 円58 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Inventories, Raw Materials & Components is 円58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.47, compared to a current price of 円64.00 — trading 47.2% above its estimated fair value. The current Inventories, Raw Materials & Components is 円58 Mil. SymBio Pharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Inventories, Raw Materials & Components is 円58 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円64.00 is trading 47.2% above its estimated GF Value™ of 円43.47. GuruFocus considers SymBio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSE:4582:

  • Inventories, Raw Materials & Components: 円58 Mil
  • GF Value™: 円43.47 vs. price of 円64.00 (47.2% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
27GF Score

Get the complete analysis for TSE:4582

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円64.00
Price
円43.47
GF Value